Evidence map›Paper›PMID 37900169›Full record

ReviewFrontiers in pharmacology2023

Advances in the research of sulfur dioxide and pulmonary hypertension.

Xin Liu, He Zhou, Hongsheng Zhang, Hongfang Jin, Yan He

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Xin LiuDepartment of Pediatric Cardiac Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
He ZhouDepartments of Medicine and Physiology, Tulane University School of Medicine, New Orleans, LA, United States.
Hongsheng ZhangDepartment of Pediatric Cardiac Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Hongfang JinDepartment of Pediatrics, Peking University First Hospital, Beijing, China.
Yan HeDepartment of Pediatric Cardiac Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Beijing Anzhen Hospital · CNCapital Medical University · CNPeking University · CNTulane University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary hypertension (PH) is a fatal disease caused by progressive pulmonary vascular remodeling (PVR). Currently, the mechanisms underlying the occurrence and progression of PVR remain unclear, and effective therapeutic approaches to reverse PVR and PH are lacking. Since the beginning of the 21st century, the endogenous sulfur dioxide (SO

Indexed as

aspartate transaminasegaseous signaling moleculepulmonary hypertensionpulmonary vascular remodelingsulfur dioxide

Identifiers

PMID37900169
PMCPMC10602757
OpenAlexW4387569631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.